MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,769K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sales and maturities of marketab...
Stock-based compensation expense
Other segment items
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Accrued expenses and other liabi...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total research and development expense
26,389
39,210
45,490
92,088
Total general and administrative
5,329
5,069
4,859
17,730
Stock based compensation
3,381
3,729
4,585
16,135
Other segment items
-2,166
-2,568
-10,067
-12,471
Net loss
-32,933
-45,440
-44,867
-42,049
Stock-based compensation expense
3,381
3,729
4,585
4,517
Depreciation and amortization expense
104
104
104
104
Accretion of premium and discounts on marketable securities
542
581
808
1,075
Income tax benefit
-
-
-6,356
-
Prepaid expenses and other current assets
2,009
-1,970
2,332
938
Other assets
0
-88
-2,339
1,081
Accounts payable
612
-3,499
9,430
-5,329
Accrued expenses and other liabilities
-5,645
-2,709
9,729
5,524
Operating lease liabilities
-52
-53
-47
-48
Net cash used in operating activities
-37,084
-46,391
-28,223
-40,375
Purchases of marketable securities
33,810
74,546
43,791
14,780
Sales and maturities of marketable securities
68,125
104,284
90,383
56,083
Net cash provided by investing activities
34,315
29,738
46,592
41,303
Proceeds from issuance of common stock upon exercise of stock options
0
871
0
58
Stock repurchase
-
-
0
11,426
Proceeds from issuance of common stock under employee stock purchase plan
0
132
0
63
Issuance of restricted stock units
0
746
0
0
Net cash provided by (used in) financing activities
0
257
0
-11,305
Net (decrease) increase in cash and cash equivalents
-2,769
-16,396
18,369
-10,377
Cash and cash equivalents at the beginning of period
79,317
95,713
77,344
64,696
Cash and cash equivalents at the end of period
76,548
79,317
95,713
77,344
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Sales and maturities
of marketable...
$68,125K
(-78.99%↓ Y/Y)
Net cash provided by
investing activities
$34,315K
(-65.99%↓ Y/Y)
Canceled cashflow
$33,810K
Net (decrease)
increase in cash and cash...
-$2,769K
(-112.03%↓ Y/Y)
Canceled cashflow
$34,315K
Stock-based compensation
expense
$3,381K
(-70.90%↓ Y/Y)
Accounts payable
$612K
(-86.05%↓ Y/Y)
Depreciation and
amortization expense
$104K
(-50.00%↓ Y/Y)
Purchases of marketable
securities
$33,810K
(-84.86%↓ Y/Y)
Net cash used in
operating activities
-$37,084K
(41.54%↑ Y/Y)
Canceled cashflow
$4,097K
Other segment items
-$2,166K
Net loss
-$32,933K
(53.90%↑ Y/Y)
Accrued expenses and
other liabilities
-$5,645K
(-116.95%↓ Y/Y)
Canceled cashflow
$2,166K
Prepaid expenses and
other current assets
$2,009K
(215.26%↑ Y/Y)
Accretion of premium and
discounts on marketable...
$542K
(-82.29%↓ Y/Y)
Operating lease
liabilities
-$52K
(45.26%↑ Y/Y)
Total research and
development expense
$26,389K
Total general and
administrative
$5,329K
Stock based
compensation
$3,381K
Buy us a coffee
Atea Pharmaceuticals, Inc. (AVIR)
Atea Pharmaceuticals, Inc. (AVIR)